1 | Belantamab mafodotin (D11595) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
(D11595) 💬
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬
| 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬
|
2 | Belantamab mafodotin 1.9 mg/kg (8 weeks) (D11595) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
(D11595) 💬
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬
| 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬
|
3 | Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages (D11595) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
(D11595) 💬
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬
| 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬
|
4 | Belantamab mafodotin 2.5 mg/kg (4 weeks) (D11595) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
(D11595) 💬
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬
| 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬
|
5 | Belantamab mafodotin 2.5 mg/kg (6 weeks) (D11595) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
(D11595) 💬
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬
| 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬
|
6 | Belantamab mafodotin 2.5 mg/kg (8 weeks) (D11595) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
(D11595) 💬
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬
| 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬
|